Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : AstraZeneca UK Limited
Femme et Homme Max 99 ans
AstraZeneca UK Limited
MAJ Il y a 5 ans
Treatment with medications that prevent the formation of blood clots, in the primary prevention of heart disease in patients with a stable lung condition called Chronic Obstructive Pulmonary Disease (COPD)
Background and study aims Chronic obstructive pulmonary disease (COPD) is the collective name for a group of diseases which affect the lungs. People who suffer from COPD have difficulty breathing, whi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca UK Limited
MAJ Il y a 5 ans
Real life effectiveness in asthma of Symbicort® Single Inhaler Therapy (RELEASE)
The primary objective of the study is to compare Symbicort® (budesonide 160 µg/inhalation and formoterol fumarate dihydrate 4.5 µg /inhalation) as Single Inhaler Therapy, with a Subject’s previous the...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca UK Limited
MAJ Il y a 5 ans
RAPID - An Open-Label, Randomised, Multicentre Phase IIIb Study to Evaluate the Efficacy and Tolerability of Quetiapine IR (Immedicate Release), over 14 days, in Acute Schizophrenia / Schizoaffective Disorder (Rapid versus Covential Titration)
The objectives of this study are to evaluate the efficacy and tolerability of quetiapine IR (Immediate Release), over 14 days, in subjects with acute schizophrenia or schizoaffective disorder, followi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations